(Total Views: 364)
Posted On: 09/14/2022 7:45:07 PM
Post# of 1418
Eric Topol@EricTopol
"Important @NEJM report on the protection rendered by high mucosal IgA vs Omicron, whether or not prior Covid, with 65% reduction of breakthrough infections, effect not related to high levels of IgG antibodies"
https://www.nejm.org/doi/full/10.1056/NEJMc2209651
Gerald Commissiong@G_Commish
"3CLpro cleaves IgA. We have IP on this. One of the reasons Tollovid is a big deal"
and that is what uplisting dreams of made of. Todos knows a lot more than investors.
"Important @NEJM report on the protection rendered by high mucosal IgA vs Omicron, whether or not prior Covid, with 65% reduction of breakthrough infections, effect not related to high levels of IgG antibodies"
https://www.nejm.org/doi/full/10.1056/NEJMc2209651
Gerald Commissiong@G_Commish
"3CLpro cleaves IgA. We have IP on this. One of the reasons Tollovid is a big deal"
and that is what uplisting dreams of made of. Todos knows a lot more than investors.
(1)
(0)
